Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Anti-CAR Immunity Drives Acquired Therapeutic Resistance to GD2-CAR T Cell Therapy in Diffuse Midline Glioma.
Journal: medRxiv : the preprint server for health sciences
Published: July 17, 2026
Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders.
Journal: Nature reviews. Clinical oncology
Published: March 26, 2026
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.
Journal: Blood cancer journal
Published: January 27, 2026
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.
Journal: Research square
Published: November 24, 2025
Large B cell lymphoma microenvironment archetype profiles.
Journal: Cancer cell
Published: November 15, 2024
Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.
Journal: Transplantation and cellular therapy
Published: September 26, 2024
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply.
Journal: The New England journal of medicine
Published: September 04, 2024
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.
Journal: Cancer discovery
Published: July 26, 2024
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.
Journal: The New England journal of medicine
Published: June 12, 2024
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.
Journal: Journal for immunotherapy of cancer
Published: June 07, 2024
Last Updated: 09/26/2026